Drug intelligence / Profile preview

GST-HG151

Development stage: Phase 1
Lead developer: Fujian Cosunter Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GST-HG151 is an orally administered small molecule drug candidate developed by Fujian Cosunter Pharmaceutical. It acts as an inhibitor of apoptosis signal-regulating kinase 1 (ASK1), c-Jun N-terminal kinase (JNK), and mitogen-activated protein kinase (MAPK) pathways. The drug is being investigated primarily for the treatment of non-alcoholic steatohepatitis (NASH), liver cirrhosis, and alcoholic hepatitis. Its mechanism involves modulation of key signaling pathways implicated in liver inflammation and fibrosis. As of now, it is in Phase 1 clinical trials in China for these indications[1][2][3][4][8].

Targets

JNK (Mitogen-activated protein kinase kinase kinase family)MAP3K5 (ASK1)MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on GST-HG151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GST-HG151.

Explore the full profile